All In Biotech

Drug Trial Radar · NCT07146295

Implementation of Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer

Implementation of Fluorescence Imaging Using Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,150

Planned (sponsor's estimate)

Start

Apr 18, 2025

Primary completion

Feb 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Isabelle HenskensAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Canisius-Wilhelmina Hospital; Spaarne Gasthuis; Noordwest Ziekenhuisgroep; Alrijne Hospital; Dijklander Ziekenhuis; Ziekenhuisgroep Twente; Diakonessenhuis, Utrecht; ZonMw: The Netherlands Organisation for Health Research and Development
First posted
Aug 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn how to successfully introduce a new method for finding the sentinel lymph node during breast cancer surgery into routine hospital care. The method uses a dye called indocyanine green (ICG) and a special camera to see the lymph node. The sentinel lymph node is the first lymph node that cancer is likely to spread to. In the Netherlands, about 1 in 7 women develops breast cancer. Finding out whether cancer has spread to the lymph nodes is important for planning treatment and predicting outcomes. The current standard method for sentinel lymph node biopsy (SLNB) uses a radioactive tracer called radioisotope technetium-labeled (99mTc)-nanocolloid. While accurate, this method has several drawbacks: it exposes patients to radioactivity, requires an extra hospital visit or travel to another hospital due to limited nuclear medicine facilities, and is not sustainable. Surgeries using 99mTc can only take place on certain days due to logistical issues, and the signal from 99mTc can be disturbed by the tumor marker placed in the breast. ICG works as well as 99mTc for SLNB and offers several advantages: it is given during surgery (no extra visit needed), produces no radiation, and reduces costs. However, it is still not widely used in the Netherlands because hospitals may not be familiar with it or unsure how to make the switch. This study will introduce ICG step-by-step in several Dutch hospitals and evaluate how to make the change as smooth and effective as possible. It will take place in three stages: I) SLNB with 99mTc only (current practice); II) SLNB with both 99mTc and ICG (transition phase); III) SLNB with ICG only (full implementation). All study procedures take place during planned surgery, with no extra hospital visits. After surgery, participants will receive a short questionnaire (10-15 minutes) to share their experiences with the procedure. Their feedback, combined with input from healthcare providers, will help researchers develop a uniform medical protocol, an implementation guide, and educational materials for surgeons and surgical trainees. The aim is to make ICG widely available across the Netherlands, ensuring that care is less burdensome, more sustainable, and more cost-effective, while keeping treatment accessible in local hospitals.

Conditions

  • Breast Cancer
  • Sentinel Lymph Node Biopsy (SLNB)
  • Sentinel Lymph Node Detection
  • Sentinel Lymph Node
  • Lymphatic Metastasis
  • Fluorescence Imaging
  • Indocyanine Green (ICG)
  • Radioisotopes
  • Lymph Node Mapping

Interventions

  • Technetium (99mTc)Drug

    A radiopharmaceutical tracer consisting of technetium-99m (99mTc)-labelled nanocolloid used for sentinel lymph node mapping. In this study, 99mTc-nanocolloid is administered via periareolar injection with an activity of 40 MBq for the one-day protocol or 100 MBq for the two-day protocol, according to local hospital practice. Injection is performed either on the day of surgery or the afternoon before surgery. Preoperative lymphoscintigraphy is carried out to visualize lymphatic drainage. During surgery, a gamma-detection probe is used to locate and remove the sentinel lymph node(s) identified by 99mTc uptake.

  • Indocyanine GreenDrug

    Indocyanine Green (ICG) is a fluorescent dye used for intraoperative sentinel lymph node mapping. In this study, a total dose of 5 mg (2 mL) of ICG is administered via periareolar injection after induction of general anesthesia and prior to axillary incision. During surgery, near-infrared fluorescence imaging is used to visualize lymphatic drainage and identify the sentinel lymph node(s). The identified node(s) are surgically removed under fluorescence guidance. In the transition phase, fluorescence findings are cross-checked against 99mTc uptake to ensure accuracy and safety.

  • Sentinel lymph node biopsyProcedure

    Sentinel lymph node biopsy (SLNB) is a surgical procedure used to identify and remove the first lymph node(s) that drain lymph from a tumor area. In this study, SLNB is performed through a small axillary incision after mapping the sentinel lymph node(s) using either radioisotope technetium-labeled (99mTc)-nanocolloid, indocyanine green (ICG) fluorescence imaging, or a combination of both. The identified lymph node(s) are excised and sent for pathological examination to determine the presence of cancer cells. The procedure is carried out under general anesthesia as part of breast cancer surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adoption of ICG for sentinel lymph node biopsy (SLNB)Time frame: During Phase III, the post-implementation period, which is the final 12 months for hospitals in cluster 1, final 9 months for cluster 2, and final 6 months for cluster 3, within the 21-month trial.

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Noordwest Ziekenhuisgroep

    Alkmaar, Netherlands · Recruiting

  • Ziekenhuisgroep Twente

    Hengelo, Netherlands · Recruiting

  • Spaarne Gasthuis

    Hoofddorp, Netherlands · Recruiting

  • Dijklander Ziekenhuis

    Hoorn, Netherlands · Recruiting

  • Alrijne Hospital

    Leiden, Netherlands · Recruiting

  • Canisius Wilhelmina Ziekenhuis

    Nijmegen, Netherlands · Recruiting

  • Diakonessenhuis

    Utrecht, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.